Overview

A Long Term Extension Study of E2080 in Lennox-Gastaut Patients

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
To investigate the safety of long term administration of E2080 in the patients with Lennox-Gastaut syndrome who completed the E2080-J081-304 Study.
Phase:
Phase 3
Details
Lead Sponsor:
Eisai Co., Ltd.
Treatments:
Rufinamide